Avidity’s AOCs technology represents a novel approach to RNA therapeutics

Avidity’s AOCs technology represents a novel approach to RNA therapeutics:AOCs combine the specificity of monoclonal antibodies, which can target specific cell types or tissues, with the therapeutic potential of oligonucleotides, which can modulate gene expression.Versatility: This platform can be applied to a wide range of diseases, offering the potential to develop therapies for conditions that currently have limited or no treatment options.By leveraging antibodies for targeted delivery, AOCs can improve the uptake of oligonucleotides into specific cells, enhancing their therapeutic efficacy and reducing off−target effects.Avidity’s lead program targets myotonic dystrophy type 1 (DM1), a genetic disorder characterized by progressive muscle wasting and weakness. The company’s AOCs aim to deliver RNA therapeutics specifically to muscle tissues, addressing the underlying genetic cause of DM1. Preclinical and Clinical Development: Avidity is advancing its DM1 program through preclinical and clinical studies to demonstrate safety and efficacy.